Is the WaPo journalistically challenged when it comes to science? You decide. An April 6 article in the Washington Post, one ...

NIH researchers discovered that a new form of personalized cancer immunotherapy dramatically improved the treatment’s ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Immunotherapy is key for triple-negative breast cancer, but a new study finds Black women are receiving it less often than White women.

Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

A new form of tumor infiltrating lymphocyte therapy, a form of personalized cancer immunotherapy, improved the treatment’s ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

According to a recent study, researchers are developing nanotechnology that can improve the treatment of one of the most ...

versus pembrolizumab plus placebo in first line treatment for checkpoint inhibitor-naïve patients with advanced or metastatic MCC. The data from the Company's Phase 1b trial in patients with ...

Patients in the clinical trial, who had a variety of gastrointestinal tumors, also received the immune checkpoint inhibitor pembrolizumab (Keytruda) to help further boost their immune response.